Sandoz launches rivastigmine tartrate capsules, authorized generic version of Exelon® capsules
Princeton, New Jersey; July 1, 2010 -- Sandoz today announced the introduction of rivastigmine tartrate capsules, an authorized generic equivalent of the Novartis treatment Exelon® capsules, in the US. Rivastigmine tartrate capsules are indicated to treat mild to moderate dementia associated with Alzheimer's and Parkinson's diseases. Alzheimer's disease is the most common cause of dementia, accounting for 50 to 80% of dementia cases and affecting up to 5.3 million people in the US . According to the National Parkinson Foundation (NPF), approximately 40% of the 1.5 million Americans with Parkinson's disease are estimated to also develop dementia .
"Sandoz is pleased to support our broad US growth strategy with the launch of rivastigmine tartrate capsules as an authorized generic of Exelon capsules," said Don DeGolyer, President of Sandoz Inc. "The launch is an excellent example of how Sandoz and Novartis Pharmaceuticals Corporation work together to make high-quality Novartis medicines more affordable in conjunction with the entry of other generic versions of innovative products."
According to IMS Health, US sales for branded rivastigmine tartrate capsules were approximately USD 132.7 million for the 12 months ending March 2010. Sandoz will market the drug in 1.5 mg, 2 mg, 3 mg, 4.5 mg and 6 mg strength capsules, the same as Exelon. Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "strategy," "will", or similar expressions, or by express or implied discussions regarding potential future revenues from rivastigmine tartrate capsules. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that rivastigmine tartrate capsules will achieve any particular levels of revenue in the future. In particular, management's expectations could be affected by, among other things, unexpected inabilities by generic manufacturers to obtain or maintain exclusivity periods for generic rivastigmine tartrate capsules; competition in general; government, industry and general public pricing pressures; unexpected patent litigation outcomes; unexpected regulatory actions or delays or government regulation generally; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of approximately 1,000 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In addition to strong organic growth in recent years, Sandoz has made a series of acquisitions including Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE (Austria) and Oriel Therapeutics (US). In 2009, Sandoz employed around 23,000 people worldwide and posted sales of USD 7.5 billion. References  Alzheimer's Association. Alzheimer's Disease Facts and Figures 2010. Available from: http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf.  American Journal of Alzheimer's Disease and Other Dementias, Vol. 21, No. 5, 366-369 (2006). * * * For further information Sandoz US Communications: Ted Deutsch +1 609 627 5287 Sandoz Global Communications: Marija Mandic +49 8024 476 2597 Exelon® is a registered trademark of Novartis.